Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study - PubMed (original) (raw)
Review
Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study
Caroline S Fox. Trends Cardiovasc Med. 2010 Apr.
Abstract
Type 2 diabetes is a common disorder and an important risk factor for cardiovascular disease. The Framingham Heart Study is a population-based epidemiologic study that has contributed to our knowledge of cardiovascular disease and its risk factors. This review will focus on the contemporary contributions of the Framingham Heart Study to the field of diabetes epidemiology, including data on diabetes trends, genetics, and future advances in population-based studies.
Copyright © 2010. Published by Elsevier Inc.
Figures
Figure 1
Age-sex adjusted 8-year incidence rate of diabetes by body mass index category and decade among participants aged 40-55 years. Error bars represent 95% confidence intervals. Reprinted with permission from Circulation.
Figure 2
Age-and-sex adjusted population attributable risk for diabetes as compared to other standard CVD risk factors from the FHS. Reprinted with permission from Circulation.
Figure 3
Risk factors levels among participants aged 50 (left-hand side) and aged 60 (right-hand side) by diabetes (grey) and non-diabetes (black) status for A) BMI; B) Total cholesterol and LDL cholesterol; C) systolic and diastolic blood pressure. Reprinted with permission from Circulation.
Similar articles
- A healthy lifestyle mitigates the risk of heart disease related to type 2 diabetes: a prospective nested case-control study in a nationwide Swedish twin cohort.
Yang R, Xu H, Pedersen NL, Li X, Yu J, Bao C, Qi X, Xu W. Yang R, et al. Diabetologia. 2021 Mar;64(3):530-539. doi: 10.1007/s00125-020-05324-z. Epub 2020 Nov 10. Diabetologia. 2021. PMID: 33169206 Free PMC article. - Coffee consumption and risk of type 2 diabetes and heart disease.
Campos H, Baylin A. Campos H, et al. Nutr Rev. 2007 Apr;65(4):173-9. doi: 10.1111/j.1753-4887.2007.tb00297.x. Nutr Rev. 2007. PMID: 17503712 Review. - Cardiovascular disease in diabetes type 2: current concepts.
Rosengren A. Rosengren A. J Intern Med. 2018 Sep;284(3):240-253. doi: 10.1111/joim.12804. Epub 2018 Jul 18. J Intern Med. 2018. PMID: 29923339 Review. - Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial.
Daniels LB, Grady D, Mosca L, Collins P, Mitlak BH, Amewou-Atisso MG, Wenger NK, Barrett-Connor E; Raloxifene Use for the Heart (RUTH) Trial Investigators. Daniels LB, et al. Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):164-70. doi: 10.1161/CIRCOUTCOMES.112.966986. Epub 2013 Mar 12. Circ Cardiovasc Qual Outcomes. 2013. PMID: 23481531 Clinical Trial. - A systematic review of the factors associated with interest in predictive genetic testing for obesity, type II diabetes and heart disease.
Collins J, Ryan L, Truby H. Collins J, et al. J Hum Nutr Diet. 2014 Oct;27(5):479-88. doi: 10.1111/jhn.12179. Epub 2013 Nov 14. J Hum Nutr Diet. 2014. PMID: 24236642 Review.
Cited by
- Impact of SGLT-2 inhibitors on modifiable cardiovascular risk factors in Romanian patients with type 2 diabetes mellitus.
Gherbon A, Frandes M, Dîrpeş D, Timar R, Timar B. Gherbon A, et al. Diabetol Metab Syndr. 2024 Apr 16;16(1):85. doi: 10.1186/s13098-024-01326-8. Diabetol Metab Syndr. 2024. PMID: 38627784 Free PMC article. - Diabetic Vasculopathy: Molecular Mechanisms and Clinical Insights.
Jia G, Bai H, Mather B, Hill MA, Jia G, Sowers JR. Jia G, et al. Int J Mol Sci. 2024 Jan 9;25(2):804. doi: 10.3390/ijms25020804. Int J Mol Sci. 2024. PMID: 38255878 Free PMC article. Review. - SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain.
Rolek B, Haber M, Gajewska M, Rogula S, Pietrasik A, Gąsecka A. Rolek B, et al. J Cardiovasc Dev Dis. 2023 Jul 30;10(8):322. doi: 10.3390/jcdd10080322. J Cardiovasc Dev Dis. 2023. PMID: 37623335 Free PMC article. Review. - The management correlation between metabolic index, cardiovascular health, and diabetes combined with cardiovascular disease.
Zhang Y, Liu C, Xu Y, Wang Y, Dai F, Hu H, Jiang T, Lu Y, Zhang Q. Zhang Y, et al. Front Endocrinol (Lausanne). 2023 Jan 27;13:1036146. doi: 10.3389/fendo.2022.1036146. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36778594 Free PMC article. - Pharmacological Treatment of Type-2-Diabetes and Cardiovascular Comorbidities: Differences between Undocumented Migrants and Natives in Italy.
Fiorini G, Pellegrini G, Franchi M, Pincelli AI, Rigamonti AE, Corrao G, Sartorio A, Cella SG. Fiorini G, et al. Healthcare (Basel). 2022 Dec 20;11(1):4. doi: 10.3390/healthcare11010004. Healthcare (Basel). 2022. PMID: 36611464 Free PMC article.
References
- Shaw JE, et al. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14. - PubMed
- American Heart Association. Heart Disease and Stroke Statistics-2008 Update. Dallas, Texas: American Heart Association; - PubMed
- Kannel WB, et al. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979;110:281–290. - PubMed
- Splansky GL, et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: Design, Recruitment, and Initial Examination. Am J Epidemiol 2007 - PubMed
Publication types
MeSH terms
Grants and funding
- N01 HC025195/HC/NHLBI NIH HHS/United States
- N01HC25195/HL/NHLBI NIH HHS/United States
- ZIA HL006094-01/Intramural NIH HHS/United States
- N01-HC-25195/HC/NHLBI NIH HHS/United States